Cicatricial organising pneumonia associated with fibrosing interstitial pneumonia - a clinicopathological study.
cicatricial organising pneumonia
fibrosing organising pneumonia, idiopathic pulmonary fibrosis
interstitial pneumonia
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
16
05
2021
received:
28
09
2020
accepted:
07
06
2021
pubmed:
9
6
2021
medline:
1
4
2022
entrez:
8
6
2021
Statut:
ppublish
Résumé
The recent recognition of cicatricial organising pneumonia (ciOP) indicates that the ciOP may resemble or simulate fibrotic interstitial pneumonia; however, there has been great uncertainty regarding the affected populations, pathogenesis, clinical relevance and characteristics. In this study, we compared the characteristics of fibrotic interstitial pneumonia with and without ciOP. We enrolled 121 patients from the consultation archive whose pathological findings were fibrotic interstitial pneumonia and for whom follow-up clinical data were available. We reviewed these cases histopathologically and classified them according to whether or not they showed ciOP. We compared the clinicopathological features between the two groups. CiOP, histopathologically characterised by deposition of dense collagenous fibres within the alveolar space without destruction of the lung structure, was found in 48 patients (39.7%). None of the cases with ciOP experienced acute exacerbation during 12 months' follow-up. The group with ciOP had more severe diffusion impairment but this, together with restrictive ventilatory impairment, improved significantly compared to the group without ciOP. CiOP is a histopathological finding commonly found in fibrotic interstitial pneumonia. It does not relate to acute exacerbation or decrease in pulmonary function.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-290Subventions
Organisme : Ministry of Health, Labour and Welfare
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care. Med. 2013; 188; 733-748.
Belloli EA, Beckford R, Hadley R et al. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21; 259-268.
Wang P, Jones KD, Urisman A et al. Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest 2017; 152; 502-509.
Winstone TA, Assayag D, Wilcox PG et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146; 422-436.
Papiris SA, Triantafillidou C, Kolilekas L et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010; 33; 539-558.
Flaherty KR, Wells AU, Cottin V et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019; 381; 1718-1727.
King T, Schwarz M, Brown K et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care. Med. 2001; 164; 1025-1032.
King T, Tooze J, Schwarz M et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care. Med. 2001; 164; 1171-1181.
Nicholson AG, Fulford LG, Colby TV et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 2002; 166; 173-177.
Tsuchiya Y, Takayanagi N, Sugiura H et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur. Respir. J. 2011; 37; 1411-1417.
Hozumi H, Nakamura Y, Johkoh T et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 2013; 3; e003132.
Davison AG, Heard BE, McAllister WA et al. Cryptogenic organizing pneumonitis. Q. J. Med. 1983; 52; 382-394.
Tansey D, Wells AU, Colby TV et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44; 585-596.
Lohr RH, Boland BJ, Douglas WW et al. Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch. Intern. Med. 1997; 157; 1323-1329.
Yousem SA. Cicatricial variant of cryptogenic organizing pneumonia. Hum. Pathol. 2017; 64; 76-82.
Churg A, Wright JL, Bilawich A. Cicatricial organising pneumonia mimicking a fibrosing interstitial pneumonia. Histopathology 2018; 72; 846-854.
Woge MJ, Ryu JH, Bartholmai BJ et al. Cicatricial organizing pneumonia: a clinicopathologic and radiologic study on a cohort diagnosed by surgical lung biopsy at a single institution. Hum. Pathol. 2020; 101; 58-63.
Mengoli MC, Colby TV, Cavazza A et al. Incidental iatrogenic form of collagenized organizing pneumonia. Hum. Pathol. 2018; 73; 192-193.
Beardsley B, Rassl D. Fibrosing organising pneumonia. J. Clin. Pathol. 2013; 66; 875-881.
Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128; 3310-3315.
Churg A, Müller NL, Silva CIS et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am. J. Surg. Pathol. 2007; 31; 277-284.
Kondoh Y, Taniguchi H, Kawabata Y et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103; 1808-1812.
Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology 2011; 58; 525-530.
Kondoh Y, Taniguchi H, Katsuta T et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2010; 27; 103-110.
Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19; 227-235.
Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 2005; 171; 1040-1047.
Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35; 821-829.
Latsi PI, du Bois RM, Nicholson AG et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care. Med. 2003; 168; 531-537.
Collard HR, King TE, Bartelson BB et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 2003; 168; 538-542.
Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care. Med. 2003; 168; 543-548.